Zacks.com on MSN3d
GILD Stock Down on Report of Cut in HIV Prevention Spending
Gilead Sciences takes a hit after a Wall Street Journal reports state that the Trump administration is looking to slash ...
Business Insider4d
Stock of the Day: Gilead Sciences falls on report the Trump administration could slash funds for HIV prevention
Why: The stock's decline follows a report from The Wall Street Journal that the US Health and Human Services Department is considering drastic cuts to federal funding for HIV prevention in the US.
Nasdaq3d
GILD Stock Down on Report of Cut in HIV Prevention Spending
GILD boasts a market-leading portfolio of HIV treatments both for treating the disease and prevention. The company has two drugs for HIV prevention in its portfolio, Descovy and Truvada.